U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07089550) titled 'PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)' on May 28.
Brief Summary: This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.
The primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While ...